Hudson Bay Capital Management
LRMR icon

Hudson Bay Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Hudson Bay Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-377,000
Closed -$1.22M – 1391
2025
Q3 		$1.22M Buy
+377,000
New +$1.41M ﹤0.01% 832

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Hudson Bay Capital Management's LRMR Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Larimar Therapeutics (LRMR) in Q1 2026: 292,250 shares worth $1.32M. The stake represents ﹤0.01% of the portfolio and ranks #840 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in LRMR as recently as Q3 2025.

Hudson Bay Capital Management first reported a position in LRMR in Q2 2025 and has held it in 3 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Hudson Bay Capital Management held 292,250 shares of Larimar Therapeutics worth $1.32M as of Q1 2026.
  • Larimar Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • Larimar Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #840 holding.
  • Hudson Bay Capital Management first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.